Polycystic Kidney Disease (PKD)
In development stay tuned.
Polycystic Kidney Disease (PKD) in cats , discovered decades ago, is a "long-standing" genetic disease. PKD is a clinically common chronic, progressive, genetic kidney disease characterized by uncontrolled growth of cysts in the kidneys and other organs that can lead to kidney failure.
Worldwide, it is not uncommon that approximately 6% of cats may be affected by polycystic kidney. The disease has a 50% chance of being passed on to the next generation. The median survival of cats with polycystic kidney is approximately 7 years.
Currently, there are no medications available for effective treatment or long term delay of PKD in cats, mainly supportive treatments such as blood pressure control, pain relief, treatment of urinary tract infections and kidney stones, etc. There is no specific approach.
MT-6507 is an oral vasopressin receptor antagonist administered orally twice daily. MT-6507 has a unique mechanism of action that promotes only water excretion without affecting the excretion of other electrolytes such as sodium ions.
In cats with PKD, vasopressin levels are significantly higher than in normal cats. MT-6507 slows the growth of renal cysts by blocking the action of vasopressin, which promotes the growth of cysts and thus increases the size of the kidney swelling.